TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Antengene Corporation Limited ( (HK:6996) ) has issued an announcement.
Antengene Corporation Limited announced that its in-house developed Claudin 18.2 antibody-drug conjugate, ATG-022, has been granted Breakthrough Therapy designation by the China National Medical Products Administration for treating certain types of gastric cancer. This designation could enhance Antengene’s positioning in the biotech industry by potentially accelerating the development and approval process of ATG-022, offering new treatment options for patients and impacting stakeholders positively.
The most recent analyst rating on (HK:6996) stock is a Hold with a HK$1.06 price target. To see the full list of analyst forecasts on Antengene Corporation Limited stock, see the HK:6996 Stock Forecast page.
More about Antengene Corporation Limited
Antengene Corporation Limited is a global, R&D-driven, commercial-stage biotech company focused on developing first-in-class and best-in-class therapeutics for diseases with significant unmet medical needs. The company’s pipeline includes several in-house discovered programs, and it has developed a proprietary T cell engager platform. Antengene has obtained multiple investigational new drug approvals in the U.S. and Asia, and its lead commercial asset, XPOVIO, is approved in several Asia Pacific markets.
Average Trading Volume: 5,912,191
Technical Sentiment Signal: Buy
Current Market Cap: HK$4.21B
For detailed information about 6996 stock, go to TipRanks’ Stock Analysis page.